To the Editor We read with interest the Editorial by Naik and Lowes¹ and agree that there is an urgent need to advance knowledge in hidradenitis suppurativa (HS). We wish to highlight a particularly vulnerable but overlooked population with HS: those who are pregnant or seeking to become pregnant.

Even though HS disproportionately affects women of reproductive age, there remain significant knowledge gaps regarding the effect of HS and its management on fertility, pregnancy, and maternal and fetal outcomes. Other chronic inflammatory diseases have been shown to affect pregnancy in important ways, including by increasing rates of preterm birth and pregnancy loss.² Despite these findings, HS—similarly inflammatory, associated with numerous medical comorbidities, and treated with systemic agents (including biologic therapies)—is underrepresented in the literature.

致编辑我们感兴趣地阅读了Naik和Lowes ¹的社论，并同意迫切需要提高化脓性汗腺炎（HS）知识。我们希望强调一个特别脆弱但被忽视的HS人群：已怀孕或打算怀孕的人群。

尽管HS对育龄妇女的影响不成比例，但在HS及其管理对生育，怀孕以及母婴结局的影响方面，仍然存在重大的知识空白。其他慢性炎性疾病已显示出以重要方式影响怀孕，包括增加早产和妊娠流失率。^[2]尽管有这些发现，但在文献中，HS（类似的炎症性疾病，与多种医学合并症相关，并用全身性药物（包括生物疗法）治疗）的代表性不足。